New Targeted Therapy for Prostate Cancer Now Available at UF Health Radiation Oncology – Davis Cancer Pavilion
Pluvicto, a targeted therapy for progressive, PSMA-positive metastatic castration-resistant prostate cancer, has been approved for clinical use by the FDA. On April 26, UF Health Radiation Oncology became the first in the state of Florida to administer it to patients.* Pluvicto is a next generation radioligand treatment…
